Advances in Melanoma Treatments: Molecular Targeted Therapies, Immunotherapies and Vaccines
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 1762
Special Issue Editors
Interests: melanoma; novel molecular targets; targeted therapy
Interests: Melanoma; novel molecular targets; targeted therapy
Special Issue Information
Dear Colleagues,
Several therapies are currently being used for melanoma treatment, the most recent one being immunotherapy. Despite this, no treatment is fully effective at achieving long-term remission for melanoma patients. Therefore, the development of new therapeutic strategies including novel molecular targeted therapies, immune checkpoint therapies and vaccines are required to combat this deadly skin neoplasm. The use of vaccine therapy in melanoma is the most advanced and natural way of training the immune system of the patient to identify and lyse the cancer cells specifically, and in some cases even prevent the recurrence of the disease. Moreover, the use of immune checkpoint inhibitors can promote the activation of pre-existing antigen-specific CD8 T cells to combat cancer progression. On the other hand, the use of molecularly targeted therapies has also demonstrated promise in slowing/preventing the disease. Given the recent success of these therapies, it may be worth exploring their specific combinations given together or in sequence to improve overall efficacies. Several research groups are currently evaluating these approaches for the treatment of melanoma and many of these strategies are being tested in early-phase clinical trials. This Special Issue will focus on discussing the recent advances in the field as well as commenting on the future implications of these findings. Through this, we plan to emphasize the knowledge gaps that currently exist and address the potential ways that can lead to the improvement of current therapeutic approaches against melanoma.
Dr. Gagan Chhabra
Dr. Chandra Singh
Dr. Ichwaku Rastogi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- molecular targets
- DNA vaccines
- RNA vaccines
- peptide vaccines
- virus/bacteria-based vaccines
- protein vaccines
- antigen-loaded cellular vaccines
- immune checkpoints
- immunotherapies